Use of monoclonal antibodies in oncology

Monoclonal antibodies represent a fundamental cornerstone in the management of cancer. These advanced biological compounds have achieved a significant improvement of survival in patients. Among the most renown antibodies: rituximab, bevacizumab, cetuximab, trastuzumab are the most used in our local...

Full description

Bibliographic Details
Author: Enriquez-Vera, Daniel
Format: article
Status:Published version
Publication Date:2021
Country:Perú
Institution:Fundación Instituto Hipólito Unanue
Repository:Diagnóstico
Language:Spanish
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/330
Online Access:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/330
Access Level:Open access
Keyword:Anticuerpos monoclonales
Oncología
cancer
Monoclonal antibodies
Oncology
id PE_006f8755dc3ffb1c874b2a1b5f8a9a0b
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/330
network_acronym_str PE
network_name_str Perú
repository_id_str
spelling Use of monoclonal antibodies in oncologyAplicación de anticuerpos monoclonales en oncologíaEnriquez-Vera, Daniel Anticuerpos monoclonalesOncologíacancerMonoclonal antibodiesOncologycancerMonoclonal antibodies represent a fundamental cornerstone in the management of cancer. These advanced biological compounds have achieved a significant improvement of survival in patients. Among the most renown antibodies: rituximab, bevacizumab, cetuximab, trastuzumab are the most used in our local daily practice. In the last decade, immunotherapy has been positioned as an efficacious therapy for adverse diseases such as melanoma, lung, and renal neoplasms. In the nearest future, new conjugated antibodies, and CAR-T therapy will represent models of innovative strategies to cure cancer.Los anticuerpos monoclonales representan una pieza fundamental en el arsenal terapéutico en oncología. Estos compuestos biológicos de alta complejidad han logrado mejorar la supervivencia de los pacientes con cáncer. Entre los clásicos se encuentran: rituximab, bevacizumab, cetuximab, trastuzumab utilizados a diario en nuestro medio. En la última década, la inmunoterapia se ha posicionado como una terapia eficaz para neoplásias de pronóstico adverso como el melanoma, cáncer de pulmón y renal. En el futuro próximo, los nuevos conjugados de anticuerpos y la terapia con células T quiméricas se presentarán como paradigmas de terapias promisorias en el manejo del cáncer.Fundación Instituto Hipólito Unanue2021-12-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/33010.33734/diagnostico.v60i4.330Diagnóstico; Vol. 60 No. 4 (2021); 224-228Diagnostico; Vol. 60 Núm. 4 (2021); 224-2281018-28882709-795110.33734/diagnostico.v60i4reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/330/344Derechos de autor 2022 Daniel Enriquez-Verainfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/3302022-01-10T04:30:46Z
dc.title.none.fl_str_mv Use of monoclonal antibodies in oncology
Aplicación de anticuerpos monoclonales en oncología
title Use of monoclonal antibodies in oncology
spellingShingle Use of monoclonal antibodies in oncology
Enriquez-Vera, Daniel
Anticuerpos monoclonales
Oncología
cancer
Monoclonal antibodies
Oncology
cancer
title_short Use of monoclonal antibodies in oncology
title_full Use of monoclonal antibodies in oncology
title_fullStr Use of monoclonal antibodies in oncology
title_full_unstemmed Use of monoclonal antibodies in oncology
title_sort Use of monoclonal antibodies in oncology
dc.creator.none.fl_str_mv Enriquez-Vera, Daniel
author Enriquez-Vera, Daniel
author_facet Enriquez-Vera, Daniel
author_role author
dc.subject.none.fl_str_mv Anticuerpos monoclonales
Oncología
cancer
Monoclonal antibodies
Oncology
cancer
topic Anticuerpos monoclonales
Oncología
cancer
Monoclonal antibodies
Oncology
cancer
description Monoclonal antibodies represent a fundamental cornerstone in the management of cancer. These advanced biological compounds have achieved a significant improvement of survival in patients. Among the most renown antibodies: rituximab, bevacizumab, cetuximab, trastuzumab are the most used in our local daily practice. In the last decade, immunotherapy has been positioned as an efficacious therapy for adverse diseases such as melanoma, lung, and renal neoplasms. In the nearest future, new conjugated antibodies, and CAR-T therapy will represent models of innovative strategies to cure cancer.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-31
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/330
10.33734/diagnostico.v60i4.330
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/330
identifier_str_mv 10.33734/diagnostico.v60i4.330
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/330/344
dc.rights.none.fl_str_mv Derechos de autor 2022 Daniel Enriquez-Vera
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2022 Daniel Enriquez-Vera
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 60 No. 4 (2021); 224-228
Diagnostico; Vol. 60 Núm. 4 (2021); 224-228
1018-2888
2709-7951
10.33734/diagnostico.v60i4
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1863010515883655168
score 15.812429

Similar Items